Abstract:The pharmacokinetics of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) with antidepressant properties, are well established. After oral administration, the drug is almost completely absorbed from the gastrointestinal tract, and the extent of absorption is unaffected by the presence of food. Despite complete absorption, oral bioavailability in man is ≈ 50% on account of first-pass hepatic metabolism. Peak plasma fluvoxamine concentrations are reached 4 to 12 hours (enteric-coated tablets) or 2 to 8 hours (capsules, film-coated tablets) after administration. Steady-state plasma concentrations are achieved within 5 to 10 days after initiation of therapy and are 30 to 50% higher than those predicted from single dose data. Fluvoxamine displays nonlinear steady-state pharmacokinetics over the therapeutic dose range, with disproportionally higher plasma concentrations with higher dosages. Plasma fluvoxamine concentrations show no clear relationship with antidepressant response or severity of adverse effects.Fluvoxamine undergoes extensive oxidative metabolism, most probably in the liver. Nine metabolites have been identified, none of which are known to be pharmacologically active. The specific cytochrome P450 (CYP) isoenzymes involved in the metabolism of fluvoxamine are unknown. CYP2D6, which is crucially involved in the metabolism of paroxetine and fluoxetine, appears to play a clinically insignificant role in the metabolism of fluvoxamine. The drug is excreted in the urine, predominantly as metabolites, with only negligible amounts (< 4%) of the parent compound.Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state. Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs.Fluvoxamine pharmacokinetics are substantially unaltered by increased age or renal impairment. However, its elimination is prolonged in patients with hepatic cirrhosis. Fluvoxamine inhibits oxidative drug metabolising enzymes (particularly CYP1A2, and less potently and much less potently CYP3A4 and CYP2D6, respectively) and has the potential for clinically significant drug interactions. Drugs whose metabolic elimination is impaired by fluvoxamine include tricyclic antidepressants (tertiary, but not secondary, amines), alprazolam, bromazepam, diazepam, theophylline, propranolol, warfarin and, possibly, carbamazepine.

Reversible Fluoxetine-Induced Hyperthyroidism: A Case Report.

Treatment of Depressive Outpatient with Venlafaxine:An Open Clinical Trial

The Impact of Quetiapine Monotherapy or in Combination with Lithium on the Thyroid Function in Patients with Bipolar Depression: A Retrospective Study

Analysis of prescriptions of three selective serotonin reuptake inhibitors from a perspective of metabolic interactions

A case of mood disorder with severe side effects of antidepressants in association with resistance to thyroid hormone beta with a THRB mutation

The multifaceted effects of fluoxetine treatment on cognitive functions

Fluoxetine, but Not Tricyclic Antidepressants, Potentiates the 5-Hydroxytryptophan-mediated Increase in Plasma Cortisol and Prolactin Secretion in Subjects with Major Depression or with Obsessive Compulsive Disorder.

Chronic fluoxetine treatment desensitizes serotoninergic inhibition of GABA inputs and the intrinsic excitability of dorsal raphe serotonin neurons

Fluoxetine: a case history of its discovery and preclinical development

Pharmacological Differences of Serotonin Reuptake Inhibitors and Possible Clinical Relevance

Effect of Venlafaxine on Blood Pressure and QTc

Remission of treatment-resistant obsessive-compulsive disorder with 600 milligrams of fluvoxamine daily: a case report

Glucocorticoid Receptor Antagonism Augments Fluoxetine-Induced Downregulation of the 5-HT Transporter

Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update

Thyroid Functions in Patients with Bipolar Disorder and the Impact of Quetiapine Monotherapy: a Retrospective, Naturalistic Study

Overview of the Pharmacokinetics of Fluvoxamine

A Novel NR3C2 Polymorphism and the Increased Thyroid-Stimulating Hormone Concentration Are Associated with Venlafaxine Treatment Outcome in Chinese Han MDD Patients

Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review

An atypical case of serotonin syndrome with normal dose of selective serotonin inhibitors: A case report.

Interpersonal sensitivity and response to selective serotonin reuptake inhibitors in patients with acute major depressive disorder

A case of serotonin syndrome caused by venlafaxine and lithium